112 related articles for article (PubMed ID: 10513346)
1. Antiinflammatory effects of oxatomide.
Marone G; Granata F; Spadaro G; Onorati AM; Triggiani M
J Investig Allergol Clin Immunol; 1999; 9(4):207-14. PubMed ID: 10513346
[TBL] [Abstract][Full Text] [Related]
2. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells.
Patella V; de Crescenzo G; Marino O; Spadaro G; Genovese A; Marone G
Int Arch Allergy Immunol; 1996 Sep; 111(1):23-9. PubMed ID: 8753840
[TBL] [Abstract][Full Text] [Related]
3. Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes.
Mita H; Shida T
Arzneimittelforschung; 1995 Jan; 45(1):36-40. PubMed ID: 7893266
[TBL] [Abstract][Full Text] [Related]
4. Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.
Richards DM; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1984 Mar; 27(3):210-31. PubMed ID: 6200290
[TBL] [Abstract][Full Text] [Related]
5. Antiallergic anti-inflammatory effects of H1-antihistamines in humans.
Assanasen P; Naclerio RM
Clin Allergy Immunol; 2002; 17():101-39. PubMed ID: 12113215
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of mediator release from human basophils and mast cells by mizolastine.
Triggiani M; Giannattasio G; Balestrieri B; Granata F; Gelb MH; de Paulis A; Marone G
Clin Exp Allergy; 2004 Feb; 34(2):241-9. PubMed ID: 14987304
[TBL] [Abstract][Full Text] [Related]
7. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells.
de Paulis A; Cirillo R; Ciccarelli A; Condorelli M; Marone G
J Immunol; 1991 Apr; 146(7):2374-81. PubMed ID: 1706398
[TBL] [Abstract][Full Text] [Related]
8. P2X7 receptor antagonist activity of the anti-allergic agent oxatomide.
Yoshida K; Ito M; Matsuoka I
Eur J Pharmacol; 2015 Nov; 767():41-51. PubMed ID: 26463039
[TBL] [Abstract][Full Text] [Related]
9. [Oxatomide and calcium: mechanisms involved in the secretion of mast cell mediators].
Bueb JL; Landry Y
Ann Dermatol Venereol; 1990; 117 Suppl 1():5-9. PubMed ID: 1978627
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the anti-inflammatory effect of FK-506 on human mast cells.
de Paulis A; Cirillo R; Ciccarelli A; de Crescenzo G; Oriente A; Marone G
J Immunol; 1991 Dec; 147(12):4278-85. PubMed ID: 1721644
[TBL] [Abstract][Full Text] [Related]
11. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.
Casolaro V; Meliota S; Marino O; Patella V; de Paulis A; Guidi G; Marone G
J Pharmacol Exp Ther; 1993 Dec; 267(3):1375-85. PubMed ID: 7505332
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of oxatomide on oxygen-radical generation and peptide-leukotriene release from guinea pig eosinophils.
Ohmori K; Manabe H; Akuta-Ohnuma K
Arzneimittelforschung; 1998 Jan; 48(1):43-6. PubMed ID: 9522030
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
14. [Suppressive effect of oxatomide on the induction of IL2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma].
Yoshizawa I; Nakajima T; Kawano Y; Noma T
Arerugi; 1994 Apr; 43(4):535-43. PubMed ID: 7913315
[TBL] [Abstract][Full Text] [Related]
15. [Oxatomide: review of pharmacodynamic effects and clinical effects in dermatology].
Cabotin PP; Janier M
Allerg Immunol (Paris); 1990 Feb; 22(2):61-9, 72. PubMed ID: 1690009
[TBL] [Abstract][Full Text] [Related]
16. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Patella V; Bouvet JP; Marone G
J Immunol; 1993 Nov; 151(10):5685-98. PubMed ID: 7693815
[TBL] [Abstract][Full Text] [Related]
17. Oxatomide and derivatives as inhibitors of mediator release from a mast cell model. Structure-activity relationships.
Paulussen JJ; Fischer MJ; Roelofsen EP; Horbach DA; de Mol NJ; Janssen LH
Arzneimittelforschung; 1996 May; 46(5):496-501. PubMed ID: 8737634
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 1-[3-[4-(diphenylmethyl)-1-priperazinyl]-propyl]-1,3-dihydro-2H-benzimidazol-2- one (oxatomide) on contraction of canine bronchial muscle].
Fujii K; Yonehara S; Takasugi S; Ueda T; Mukai M
Nihon Heikatsukin Gakkai Zasshi; 1983 Feb; 19(1):47-54. PubMed ID: 6141314
[TBL] [Abstract][Full Text] [Related]
19. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release.
Stellato C; Cirillo R; de Paulis A; Casolaro V; Patella V; Mastronardi P; Mazzarella B; Marone G
Anesthesiology; 1992 Nov; 77(5):932-40. PubMed ID: 1280014
[TBL] [Abstract][Full Text] [Related]
20. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells.
Amon U; Gibbs BF; Buss G; Nitschke M
Inflamm Res; 2000 Mar; 49(3):112-6. PubMed ID: 10807498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
